Samantha Budd Haeberlein, PhD, is Vice President and Head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen. Samantha leads the team accountable for Global Clinical Development for Biogen’s Alzheimer’s disease portfolio.
Samantha has more than seventeen years of pharmaceutical industry experience across Research, Translational Science/Medicine and Clinical Development and is recognized internationally for leadership in Alzheimer’s disease drug discovery, diagnostics and clinical development.
Samantha came to Biogen in 2015 from AstraZeneca where she held roles in the US, Canada and Sweden most recently as Vice President of Translational Science & Global Program Lead in Alzheimer’s disease. Samantha helped build the Neuroscience Virtual R&D group an experimental business model, and successfully led an Alzheimer’s project through to Ph3 in the virtual setting, as well as securing a peer pharma collaboration for this program. Prior to that, Samantha was Head of the Neurology Disease Area Strategy at AstraZeneca, building capabilities and collaborations and developing multiple programs in Multiple Sclerosis, Alzheimer’s & Parkinson’s disease, and was for 9 years a member of the Neuroscience Leadership team. In this role, Samantha established a number of strategic and award-winning collaborations with leading centers of Clinical and Basic Research in Alzheimer’s disease, and built the first integrated Translational Sciences function, as well as contributing to multiple candidate drug transitions and the early development of the Neurology portfolio.
Samantha is currently on the Board for The Boston Home, a residence and center for care of adults with advanced, progressive neurological diseases and has previously served on the Board for Rodin Therapeutics and the Board for the Stockholm Brain Institute. Samantha has a BSc with honors and a Ph.D. in Biochemistry from the University of Dundee in Scotland. She was a Wellcome Trust International Research Fellow and Instructor at Harvard Medical School as well as a Postdoctoral Research Associate at Children’s Hospital in Boston and conducted research at The Burnham Institute in San Diego.